There has been a progressive increase in the global rate of obesity over the past two decades, and it is predicted that approximately half of the US population will be obese by the year 2030 (ref. 1). Obesity confers a strong risk factor for associated disorders, such as insulin resistance and type 2 diabetes, atherosclerosis, cardiovascular disease and cancer 2, 3 . Despite enormous efforts in academia and industry to develop anti-obesity medications, the drugs that have reached the market thus far have had only marginal effects (in the range of 3-10%) on body weight, and most have been withdrawn from the market owing to their side effects 4 . Therefore, there is an urgent need for safe and effective medical treatments for obesity.
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Leptin is a protein hormone involved in the regulation of a plethora of physiological parameters, including food intake, energy expenditure, reproduction, immune function and glucose homeostasis [5] [6] [7] [8] . The discovery of leptin more than two decades ago raised much hope that an effective treatment had been found for obesity 9 ; however, except for the rare cases of obesity caused by a genetic deficiency of leptin, treatment with this hormone alone does not reduce the body weight of the majority of individuals with obesity who are hyperleptinemic [10] [11] [12] [13] .
A number of pathologies have been proposed to reduce leptin signaling-and thus to induce leptin resistance-during the progression of obesity [14] [15] [16] [17] [18] [19] [20] [21] [22] . However, a complete understanding of the molecular mechanisms that underlie these pathologies is missing. One such mechanism is endoplasmic reticulum (ER) stress. The ER is an intracellular organelle that is responsible for the synthesis of membrane and secretory proteins, as well as cholesterol and lipids. Perturbations in ER homeostasis lead to ER stress, which activates a complex signaling cascade called the unfolded protein response (UPR) [23] [24] [25] . UPR activation maintains or re-establishes ER homeostasis as a cellular defense mechanism, and basal activity of this signaling cascade is required for normal physiological processes [23] [24] [25] . Despite the beneficial role of acute UPR signaling in the maintenance of cellular homeostasis, prolonged ER stress contributes to the pathogenesis of many diseases, including type 2 diabetes, cancer, atherosclerosis and inflammatory and neurodegenerative diseases [24] [25] [26] [27] .
Recently, we and others have documented that increased ER stress in hypothalamic neurons has a key role in the development of leptin resistance, and consequently, obesity [28] [29] [30] . The induction of ER stress alone is sufficient to trigger leptin resistance in otherwise leptin-sensitive lean animals, and alleviation of this stress in mice with obesity by agents such as 4-phenylbutyrate (4-PBA) or tauroursodeoxycholic acid (TUDCA) can potentiate the weight-reducing and anorectic effects of exogenously administered leptin 28 . However, because of their low efficacy, 4-PBA and TUDCA could not have been used as leptin sensitizers in humans. The spliced form of X-box binding protein-1 (XBP1s) is one of the cardinal regulators of ER homeostasis 31, 32 , and we and others have previously reported a positive role of XBP1s in the regulation of leptin signaling 28, 33 .
On the basis of the above lines of evidence, we searched the Broad Institute Connectivity Map (CMAP) database 34 for small molecules with gene expression signatures that are highly similar to the expression profiles of tissues that overexpress XBP1s, and of tissues obtained from mice treated with 4-PBA and TUDCA 35 . We identified celastrol as a highly potent leptin sensitizer that a r t i c l e s 1 0 2 4 VOLUME 22 | NUMBER 9 | SEPTEMBER 2016 nature medicine reduces food intake and body weight in mice with DIO, but that has little effect on lean, ob/ob or db/db mice 35 . Celastrol was obtained from a combined analysis of different CMAP outputs by using six different gene expression signatures from livers and hypothalamus, which show reduced ER stress and leptin resistance 35 . Thus, we reasoned that the gene expression profile of celastrol itself would serve as a consolidated signature to search compounds that act as leptin sensitizers and also validate our strategy for discovering new leptin sensitizers.
By using this approach, we identified withaferin A as having a similar gene expression profile to that of celastrol. Withaferin A is a steroidal lactone that belongs to the withanolide family of compounds, which are isolated from the leaves, berries and roots of the medicinal plant Withania somnifera (also known as winter cherry or ashwagandha) 36 . Withaferin A is one of more than 50 chemicals identified in the W. somnifera extract 36 . The extract of W. somnifera has been used in traditional Indian medicine for centuries to treat tumors, stress, anxiety, aging, inflammation and autoimmune diseases 37, 38 .
RESULTS

Identification of withaferin A as a leptin sensitizer
We hypothesized that compounds with gene expression signatures similar to that of celastrol, which is a strong leptin sensitizer 35 , will have similar effects on leptin sensitization. To test this hypothesis, we created a celastrol gene expression signature from the microarrays of mouse embryonic fibroblasts (MEFs) treated with vehicle or celastrol. We chose the 20 genes that were most highly upregulated and another 20 genes that were most heavily downregulated by celastrol treatment (Fig. 1a,b) , and then selected available human probes that matched these mouse genes (Supplementary Fig. 1a ). This human-probe combination was used for a query in CMAP as the gene expression signature of celastrol (see Online Methods for detailed information about CMAP). Certain conditions, such as ER stress, can have distinctive gene expression profiles for the same phenotype: reduced ER stress can have both increased and reduced chaperone expression profiles 35 . Therefore, we used the absolute enrichment score as the metric from CMAP analysis results, as we did during the discovery of celastrol, and identified withaferin A as one of three top-ranking chemical compounds, the first of which was celastrol itself (Fig. 1c) . CMAP scored withaferin A as the second-closest molecule to celastrol when the enrichment score itself was used (Supplementary Fig. 1b) . To check whether gene expression profiles obtained in different settings for celastrol and withaferin A also show the same relationship, we obtained microarray results for celastrol and withaferin A from the CMAP database and again observed a high level of similarity in the heat-map analysis between the first 50 genes that were upregulated or downregulated (Fig. 1d) .
To consider the possible effects of leptin sensitizers on the hypothalamus, we also investigated whether celastrol and withaferin A create similar gene expression profiles in the hypothalamus. Analysis of the microarray results showed a similarity between the hypothalamic gene expression profiles of celastrol-and withaferin-A-treated mice in the heat-map analysis (Fig. 1e) . Heat-map analysis of a microarray result would provide only qualitative measures. To be able to quantitatively analyze the similarity between the hypothalamic gene expression signatures of celastrol and withaferin A, and also to compare this analysis with the results obtained from cell-line experiments in CMAP, we first quantified the degree of correlation between gene expression signatures of celastrol and withaferin A from the CMAP cell line in Figure 1d by using Pearson product-moment correlation analysis. Indeed, we found a high degree of correlation, with an r value of 0.79 (Fig. 1f) . This analysis was consistent with the CMAP analysis, which showed -0. a high degree of correlation between the expression profiles of celastrol and withaferin A. Next, we used Pearson's correlation analysis on hypothalamic gene expression profiles of these two molecules (Fig. 1e) .
We found that the degree of correlation was even higher between the hypothalamus gene expression signatures of celastrol and withaferin A, with an r value of 0.882 (Fig. 1g) . These results provide strong support for the idea that withaferin A creates similar alterations in the hypothalamic gene expression profile of mice with DIO, as compared to those after celastrol treatment. On the basis of the similarity between the gene expression profiles of celastrol and withaferin A, we tested the hypothesis that withaferin A would induce physiological responses similar to those of celastrol by acting as a leptin sensitizer.
Withaferin A reduces body weight of mice with DIO To assess whether withaferin A acts as a leptin sensitizer and leads to weight loss, mice with DIO were treated either with vehicle or withaferin A. The vehicle-treated group retained a stable body weight throughout the study (Fig. 2a,b) . However, withaferin-A treatment of mice with DIO led to a highly significant decrease in body weight during the treatment period (P < 0.001) (Fig. 2a) , equivalent to a total weight loss of 22.8% (Fig. 2b) .
One of the most pronounced effects of leptin treatment is the suppression of food intake. Withaferin-A-treated mice also consumed significantly lower amounts of food (62%) than the vehicle group (P < 0.001) ( Fig. 2c and Supplementary Fig. 2a,b) . Consistently with increased leptin sensitivity, circulating leptin concentrations in the withaferin-A-treated group were significantly lower than those in the vehicle group (Fig. 2d) . Next, we used dual-energy X-ray absorptiometry (DEXA) scans to determine fat and muscle mass and found that the withaferin-A-treated group showed significantly lower fat mass of 35% (P < 0.001), relative to the fat mass of the vehicle group, without any change in total lean mass (Fig. 2e) .
To address the possibility that the reduction in food intake and the subsequent weight loss derives from a toxic effect of the treatment, we reasoned that toxicity should be observed in both lean animals and those with obesity, whereas a leptin sensitizer should reduce body weight and food intake preferentially in mice with DIO. Neither vehicle treatment nor withaferin-A treatment altered the body weight of lean mice (Fig. 2f,g ). Food intake of lean mice was also not affected by withaferin A (Fig. 2h) , and we observed no significant differences in plasma leptin between the groups (Fig. 2i) . DEXA scans revealed that withaferin-A administration did not change the fat or lean mass of lean mice (Fig. 2j) . However, when we administered withaferin A to wild-type mice that were heavier (~30 g) than lean mice (~25 g) and were kept on a chow diet, withaferin-A administration led to a significant decrease in body weight (body weight, P < 0.01; percentage change in body weight, P < 0.001), as well as lower food intake (P < 0.001), relative to mice given vehicle treatment ( Supplementary  Fig. 2c-e) , which indicates that the effect of withaferin A on bodyweight loss is not due specifically to high-fat-diet (HFD) feeding, but is related to the absolute body weight of the mice.
Withaferin A minimally affects ob/ob and db/db mice Next, we administered withaferin A to db/db and ob/ob mice to test for the dependency of the effects of the compound on leptin signaling because both these strains lack this pathway (the former owing to the absence of the receptor and the latter owing to the absence of the hormone). The administration of withaferin A to male db/db mice did not produce body-weight reduction, whereas the vehicle-treated group gained body weight during the experimental period (Fig. 3a) . Db/db mice treated with withaferin A gained a slight amount of body weight relative to their weight during the pretreatment period, but the vehicle-treated group gained more weight when compared to the withaferin-A-treated group (14% versus 4% increase in body weight, respectively; vehicle versus withaferin A, P < 0.001) (Fig. 3b) . These findings indicate that the influence of withaferin A on body weight in db/db mice is minimal when compared to its effect in mice with DIO ( Figs. 2a and 3a) . We observed a slightly (but not significantly) lower amount of food consumption from withaferin-A-treated db/db mice, as compared to the vehicle-treatment group (Fig. 3c) , and no difference in leptin concentrations between the two groups ( Fig. 3d) .
Withaferin-A administration also did not alter the fat or lean mass of db/db mice significantly when compared to vehicle treatment (Fig. 3e) . The same withaferin-A treatment in leptin-deficient ob/ob mice led to a small but insignificant decrease in body weight ( Fig. 3f) , whereas vehicle-treated ob/ob mice displayed a slight gain in body weight, during the treatment period ( Fig. 3f,g ). However, at the end of trial, an analysis of percentage changes in the body weight of vehicle-treated and withaferin-A-treated ob/ob mice resulted in a significant difference (Fig. 3g) . There was no significant difference in absolute body weight between two groups at the end of treatment (Fig. 3f) . Food intake ( Fig. 3h ) and fat mass ( Fig. 3i ) in withaferin-Atreated ob/ob mice were slightly (but significantly) lower than in the vehicle-treated group, but there was no difference in lean mass between the two groups (Fig. 3i) ; the total fat-mass reduction was much smaller than that seen in mice with DIO (35% versus 7% reduction in fat, mice with DIO versus ob/ob mice) (Figs. 2e and 3i).
Withaferin A increases the potency of leptin Although lean mice are sensitive to acute administration of leptin 39 , it is known that mice with DIO do not respond to exogenous leptin treatment, as a result of their leptin resistance 40, 41 . To provide further support for the leptin-sensitizing role of withaferin A, we first tested the potency of leptin on the regulation of food intake and body weight in leptin-resistant DIO mice, with or without withaferin-A treatment. First, we administered either vehicle or withaferin A to mice with DIO and then injected saline or leptin on the second day of vehicle or withaferin-A treatment. The group treated with vehicle plus leptin (Veh + Lep) showed no significant change in food consumption when compared to the group treated with vehicle and saline (Veh + Sal) ( Supplementary Fig. 3a ). However, withaferin-A treatment alone (Wit A + Sal) led to significantly lower food intake (42%) when compared with the Veh + Lep group (P < 0.01). Despite already showing reduced food consumption, mice that received a leptin injection after withaferin-A treatment (Wit A + Lep) further lowered their food intake by 65% relative to the Veh + Sal group, or by 71% relative to the Veh + Lep group (P < 0.001) (Supplementary Fig. 3a) . Additionally, in parallel to the alteration of food intake, body weight was significantly lower in the Wit A + Lep group than in the other three cohorts ( Supplementary Fig. 3b ). Leptin caused no significant changes in the body weight of the Veh + Lep group when compared to the Veh + Sal group (Supplementary Fig. 3b ).
Ob/ob mice are sensitive to the administration of exogenous leptin 39, 42, 43 . However, we chose a low dose of leptin, which is minimally effective in the ob/ob mice, to investigate whether withaferin A can also increase the sensitivity of ob/ob mice to extremely low doses of leptin. Ob/ob mice were pretreated with vehicle or withaferin A. After administering withaferin-A treatment, we divided each set of mice into two subgroups and further treated these groups with either saline or leptin. The low dose of leptin did not lead to significant loss of body weight, but it did block further weight gain when compared with the Veh + Sal group (Supplementary Fig. 3c ). Withaferin-A treatment alone did not cause any weight loss. However, the Wit A + Lep group lost significantly more weight than did the Veh + Sal and Wit A + Sal groups (Supplementary Fig. 3c ). Leptin treatment in the vehicle group led to a 29% lower food intake relative to that for the vehicle and saline group ( Supplementary Fig. 3d) ; however, the same dose of leptin in the withaferin-A-treated group led to a 40% lower food consumption when compared to the withaferin A and saline group (Supplementary Fig. 3d ).
The hypothalamic sites of action of celastrol and withaferin A We have previously shown that celastrol increases the sensitivity of the leptin-receptor signaling system in the whole hypothalamus 35 . However, we had not previously determined which nuclei in the hypothalamus were affected by celastrol treatment. Arcuate nucleus (ARC), ventromedial hypothalamus (VMH) and dorsomedial hypothalamus (DMH) have been suggested as crucial sites for leptin action [44] [45] [46] . Thus, we first determined the status of STAT3(Tyr705) phosphorylation in ARC, VMH and DMH of mice with DIO by using immunohistofluorescence (IHF) analysis with or without celastrol treatment. Mice with DIO given either vehicle or celastrol subsequently received saline or a bolus dose of leptin. Afterward, total fluorescence intensities (TFIs, hereafter intensities) and total cell numbers (TCN, hereafter cell numbers) of phosphorylated (p) STAT3(Tyr705)-positive cells in ARC, VMH and DMH were determined for each mouse, and experiments from two independent cohorts were combined for final analysis. Celastrol alone (Cel + Sal) led to significantly greater pSTAT3(Tyr705)-positive cell numbers in the DMH group than in the vehicle group (Veh + Sal) (P < 0.001) (Supplementary Fig. 4a,b) . Leptin treatment alone (Veh + Lep) also led to larger pSTAT3(Tyr705)-positive cell numbers, as compared to Veh + Sal ( Supplementary  Fig. 4a,b) , whereas celastrol and leptin treatment (Cel + Lep) resulted in greater pSTAT3(Tyr705)-positive cell numbers than did Veh + Lep (Supplementary Fig. 4a,b) . In the VMH, Cel + Sal mice show significantly larger pSTAT3(Tyr705)-positive cell numbers relative to the Veh + Sal group (P < 0.05) (Supplementary Fig. 4c,d) , and Cel + Lep administration produced greater pSTAT3(Tyr705)-positive cell numbers than did the Veh + Lep group (Supplementary Fig. 4c,d) . In the ARC, celastrol treatment led to greater pSTAT3(Tyr705)-positive cell numbers relative to the Veh + Sal group, whereas Cel + Lep did not show any significant difference in pSTAT3(Tyr705)-positive cell numbers when compared to Veh + Lep ( Supplementary  Fig. 4e,f) . We detected significantly greater pSTAT3(Tyr705) intensities only in Cel + Lep mice, when compared to the Veh + Sal group (Supplementary Fig. 4a-f) . Taken together, our data show that celastrol potentiates leptin signaling mainly in the DMH and VMH.
We then investigated how STAT3(Tyr705) phosphorylation is modulated by withaferin-A treatment in the whole hypothalamus. Mice with DIO first received a single dose of vehicle or withaferin A, and 15 h later, mice were given either saline or leptin. Leptin injection in vehicle-treated mice with obesity (Veh + Lep) did not produce a (Fig. 4a) . However, a single injection of withaferin A (Wit A + Sal) led to significantly higher levels of basal STAT3(Tyr705) phosphorylation when compared to the Veh + Sal and Veh + Lep groups (P < 0.001). The administration of leptin after injection of withaferin A (Wit A + Lep) created a much greater degree of STAT3(Tyr705) phosphorylation than in any other group (Fig. 4a) .
We next analyzed STAT3(Tyr705) phosphorylation levels in DMH, VMH and ARC by an IHF staining approach. In the DMH, mice treated with withaferin A alone (Wit A + Sal) showed significantly higher levels of both pSTAT3(Tyr705)-positive cell numbers and intensities compared to the Veh + Sal group (cell numbers, P < 0.01; intensities, P < 0.05) (Fig. 4b,c) , whereas withaferin A plus leptin treatment (Wit A + Lep) produced higher pSTAT3(Tyr705)-positive cell numbers and intensities when compared to the Veh + Lep group (Fig. 4b,c) . In the VMH, Wit A + Sal treatment led to significantly greater pSTAT3(Tyr705) intensities than did Veh + Sal treatment (P < 0.05) (Fig. 4d,e) , whereas both pSTAT3(Tyr705)-positive cell numbers and intensities of Wit A + Lep mice were significantly greater than those of the Veh + Lep group (P < 0.01) (Fig. 4d,e) . In the ARC, Wit A + Sal mice showed markedly higher levels of both pSTAT3(Tyr705)-positive cell numbers and intensities when compared with Veh + Sal group (Fig. 4f,g ); in addition, Wit A + Lep treatment produced significantly higher pSTAT3(Tyr705) intensities in ARC than Veh + Lep (P < 0.05) (Fig. 4f,g ). In sum, withaferin A, similarly to celastrol, sensitizes leptin receptor signaling substantially in the DMH and VMH.
Next, we analyzed gene expression levels of agouti-related peptide (Agrp), neuropeptide Y (Npy), pro-opiomelanocortin (Pomc) and suppressor of cytokine signaling 3 (Socs3) in the whole hypothalamus of mice with DIO treated with vehicle or withaferin A. Withaferin-A treatment led to significantly higher Agrp and Socs3 expression and significantly lower Pomc expression as compared to vehicle treatment, without leading to a change in NPY expression (Fig. 5a) .
Withaferin A reduces ER stress
We first treated the tuberous sclerosis complex 2 (TSC2) knockout (Tsc2 −/− ) MEFs, which are characterized by intrinsically elevated ER stress 47 , with increasing doses of withaferin A, and documented that withaferin A greatly reduced PERK(Thr980) phosphorylation when compared to vehicle treatment, which indicates that withaferin A reduces ER stress; the results of four independent experiments are presented in Supplementary Figure 5a ,b. We then investigated the status of ER stress in the hypothalamus of withaferin-A-treated mice. Five independent cohorts of mice were used in this experiment (Supplementary Fig. 5c ) and combined analysis was performed. Results from these experiments documented that withaferin-A treatment led to less PERK(Thr980) phosphorylation in the hypothalamus, in a highly significant manner (Fig. 5b) , which indicates that withaferin A alleviates hypothalamic ER stress. We next investigated the transcript levels of Xbp1s, C/EBP homologous protein (Ddit3) and various other ER chaperones in the whole hypothalamus of mice treated with either vehicle or withaferin A. Most of the expression levels of ER chaperones were unaltered by withaferin-A treatment, except glucose-regulated protein 78 (also known as heat shock protein 5, Hspa5), whose expression level was significantly lower in the withaferin-A treatment group than in the vehicle-treated group (Fig. 5c) .
Withaferin A has been proposed as an inhibitor of heat-shock protein 90 (HSP90, encoded by Hsp90) 48 . HSP70 (encoded by Hspa1a) expression has been used as an indicator of HSP90 activity, and Hspa1a levels were reported to be increased in the conditions that HSP90 activity is inhibited 49 . Therefore, we measured HSP70 protein amount in the hypothalamus from mice with DIO given either vehicle treatment or withaferin A. As shown in Supplementary Figure 5d , withaferin-A administration did not alter HSP70 protein levels in the hypothalamus, despite the same dose of withaferin A effectively suppressing food intake of mice with DIO in the same experiment (data not shown), which indicates that withaferin A affects food intake and body weight of mice independently of HSP90 inhibition in the hypothalamus.
Furthermore, withaferin A has been suggested to be an inhibitor of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway 50 . We thus investigated whether withaferin-A treatment inhibits NF-κB activity in the hypothalamus. Analysis of NF-κB target genes showed that most of the NF-κB target genes were unaltered with withaferin-A treatment ( Supplementary  Fig. 5e ), indicating that the action of withaferin A does not rely on the inhibition of NF-κB in the hypothalamus at the doses administered in our study.
Withaferin A blocks reduction in energy expenditure
Food restriction or starvation reduces basal metabolic energy expenditure 41, 51 . However, despite its anorexigenic ability, leptin does not lead to a reduction in energy expenditure 41 . To investigate the metabolic changes induced by withaferin A, we undertook metabolic chamber experiments and determined the values for energy expenditure, for physical-activity levels and for the respiratory exchange ratio (RER) at earlier times of treatment, when leptin action is at its highest, in the mice with DIO. Withaferin-A treatment in mice with DIO led to a substantial decrease in food intake (data not shown). But despite this reduction, no significant differences in energy expenditure were seen between the vehicle-and withaferin-A-treated mice with DIO ( Fig. 6a) . However, significantly lower RER values in the withaferin-A-treated mice, relative to the vehicle-treated control group, were noted both in dark and light cycles (Fig. 6b) , which suggests that withaferin-A treatment increased the utilization of fat as an energy source. Analysis of the activity of mice treated with withaferin A showed significantly less movement during the dark cycle than did mice given vehicle treatment, but they showed no alteration during the light cycle (Fig. 6c) . We also analyzed the metabolic parameters of ob/ob and db/db mice. Withaferin-A treatment did not create any significant changes in energy expenditure of ob/ob mice (Fig. 6d) ; however, withaferin-A treatment in ob/ob mice led to significantly lower RERs and physical activity, as compared to the vehicle treatment, in only the dark cycle (Fig. 6e,f) . Analysis of metabolic parameters in the db/db mice revealed similar regulations with withaferin A treatment (Fig. 6g-i) .
Withaferin-A treatment loses its potency to reduce body weight after 3 weeks of treatment (Fig. 2a,b) , in accordance with amelioration of hyperleptinemia (Fig. 2d) ; this result led us to reason that the effect of withaferin A on metabolic parameters in mice with DIO should also diminish with decreasing leptin levels. We thus repeated the metabolic chamber experiments after weight loss had occurred and body weight had stabilized. At the end of 18 d of treatment, the withaferin-A-treated group was substantially leaner than the vehicle group-mice in this group were consuming similar amounts of food as the vehicle group and yet not gaining further weight. We saw no significant differences in energy expenditure between the vehicleand withaferin-A-treated groups (Supplementary Fig. 6a ). RER values returned back to control levels, and no differences were noted in physical activity (Supplementary Fig. 6b,c) . Analyses of energy expenditure, RER values and activity also yielded no differences between vehicle-or withaferin-A-treated ob/ob ( Supplementary  Fig. 6d-f) or db/db (Supplementary Fig. 6g-i) mice, despite the continuing presence of obesity in these groups.
We next investigated whether withaferin-A-treatment and the consequent weight loss have positive effects on the liver and on other metabolic parameters. Analysis of liver sections after 21 d of withaferin-A treatment showed that hepatic steatosis was completely resolved in withaferin-A-treated mice (Supplementary Fig. 7a) . No difference was seen in the fat content of livers of withaferin-A-treated mice with obesity and of vehicle-treated, lean, control mice after the treatment period. Plasma alanine transaminase (ALT) and aspartate transaminase (AST) concentrations were significantly lower in withaferin-A-treated mice than in the vehicle group (P < 0.01) (Supplementary Fig. 7b,c) , indicating improved liver function. Blood cholesterol concentrations were also significantly lower in the withaferin A group than in the controls (P < 0.001) ( Supplementary  Fig. 7d ). To rule out the possibility that reduced food intake and the decrease in body weight induced by withaferin-A treatment resulted from increased thyroid activity, we measured serum triiodothyronine (T3) concentrations and found that T3 concentrations were actually lower in withaferin-A-treated mice than in the controls, which indicated that the mice had not developed thyrotoxicosis (Supplementary Fig. 7e ).
Withaferin A improves glucose homeostasis of obese mice
We next analyzed the effect of withaferin A on glucose metabolism. A glucose tolerance test (GTT) revealed significantly faster disposal of glucose from the circulation in the withaferin-A-treated mice with DIO, as compared to the vehicle-treated group (P < 0.001) (Supplementary Fig. 8a ). An insulin tolerance test (ITT) also showed a significantly greater responsiveness to insulin in the withaferin-A-treated mice with DIO than in the vehicle-treated group (P < 0.05) (Supplementary Fig. 8a ). We also found that blood glucose and insulin concentrations were lower in the withaferin-A-treated mice with DIO relative to vehicle treatment (Supplementary Fig. 8b) .
We next studied the effect of withaferin A on glucose homeostasis in lean mice. Performance of GTT and ITT of lean mice treated with withaferin A showed no difference compared to the vehicle group in glucose tolerance and insulin sensitivity ( Supplementary  Fig. 8c) , with no change in blood glucose or insulin concentrations (Supplementary Fig. 8d) . However, analysis of glucose homeostasis revealed a significant effect of withaferin-A treatment on db/db and ob/ob mouse models; clearance of glucose from the circulation was significantly faster in withaferin-A-treated db/db mice than in vehicle controls (P < 0.05) (Supplementary Fig. 8e ). There was no difference in response to insulin during the ITT between the two groups (Supplementary Fig. 8e ). Blood glucose concentrations were significantly lower in the withaferin-A-treated db/db mice than in the vehicle group (P < 0.01) (Supplementary Fig. 8f) , with no significant difference in circulating insulin concentrations ( Supplementary  Fig. 8f ). Similar results were obtained for withaferin-A-treated ob/ob mice in comparison to their controls ( Supplementary Fig. 8g,h ). Taken together, our results indicate that in addition to being an anti-obesity agent, withaferin A has antidiabetic effects that are independent of its anorexigenic capabilities.
DISCUSSION
More than two decades have passed since the historic discovery of leptin by Friedman and co-workers 9 , but no viable leptin-centric treatment for obesity has been developed to date. Soon after the initial publications on leptin, it was suggested that obesity is a condition of leptin resistance [10] [11] [12] . Over the course of the past 20 years, hopes for a leptin-oriented treatment of obesity have diminished gradually, as many attempts at re-sensitizing the brains of individuals with obesity to endogenous leptin have failed. These unsuccessful efforts to increase leptin sensitivity and utilize the hyperleptinemic state of obesity to treat the condition also contributed substantially to the debate on whether or not leptin resistance actually exists 6, 52 . Our findings on celastrol and now on withaferin A potentially change the landscape: they not only provide strong support for the concept of leptin resistance, but more importantly, they also show that the hyperleptinemic state of obesity can be leveraged for therapeutic purposes by increasing leptin sensitivity. In contrast to the major focus of drug discovery-which has been targeting a single molecule in a specific pathway (in this case, the ER-stress-signaling pathway)-here we have employed a different approach. We analyzed the outputs of various interventions that had positive effects on different aspects of the ER system. Celastrol was discoverable from reverse analysis, combination and, ultimately, absolute value-scoring algorithms of six different microarrays that were obtained from a variety of inputs, leading to outputs that improved ER homeostasis. A major challenge in the validation of such a methodology was to prove that a compound that emerged from these studies serves as a condensed platform for the discovery of new drugs. Indeed, our findings on celastrol led us to discover withaferin A, and we also thereby documented that this system-and the discovery of celastrol-were not just coincidental.
Withaferin-A treatment of HFD-fed mice with obesity and hyperleptinemia led to a robust reduction in food intake, as well as in body weight. Both changes are dependent on high levels of circulating leptin. As leptin levels gradually decrease over the treatment period, the effect of withaferin A also gradually diminishes. Additionally, no withaferin-A-induced changes in food consumption or in body weight were observed in lean mice, which have low levels of circulating leptin. However, withaferin A led to small but significant changes in body weight (percentage changes from the initial point) of ob/ob and db/db mice, probably owing to the transient decrease in food intake of these mice during the early treatment period. In both types of mice, the effect on food intake was minimal when compared to the reduction that is seen in the DIO model. Several possibilities come to mind with regard to why withaferin-A treatment might have this effect on db/db and ob/ob mice but not on lean mice. First, in addition to leptin sensitization, withaferin A might also sensitize the central nervous system to another cytokine or other circulating factors that only weakly affect the regulation of food intake and that are upregulated in mice with obesity but not in lean mice. Second, withaferin A may sensitize the brain to another hormone or cytokine that is upregulated in obesity and is part of a signaling pathway that participates in substantial cross-talk with the leptin receptor signaling system. The latter possibility is supported by our observation that the withaferin-A-associated reduction in food intake is slightly greater in ob/ob mice than in db/db mice; ob/ob mice have functional leptin receptor signaling but lack leptin, whereas db/db mice have high levels of circulating leptin, but no functional leptin receptor signaling system. Further investigation is needed to reveal the presence and identity of such potential factors. But even if they exist, their contribution to the regulation of food intake and energy balance is likely to be minimal when compared to that of leptin, as indicated by the differences between the responses of mice with DIO and ob/ob or db/db mice to withaferin A. Furthermore, the effects of withaferin A on ob/ob or db/db are transient and disappear, despite the continuation of obesity, which provides further support that the effects of withaferin A on food intake at the doses that we used are due to increased leptin sensitivity.
Withaferin A also has a more pronounced effect on blood glucose levels in ob/ob and db/db mice than does celastrol. One explanation for this may be that, in obesity models, withaferin A has a slightly higher influence on food intake and body weight of these models than celastrol, which might drive the improvement in glucose homeostasis. However, as discussed above, the alterations in food intake and body weight of withaferin-A-treated ob/ob and db/db mice were minimal. Thus, these results suggest that the positive effect of withaferin A on glucose metabolism is not merely a secondary response to weight loss, but that withaferin A also could be positively influencing antidiabetic pathways in a leptin-independent manner. This action of withaferin A is different than celastrol's effects on glucose metabolism in ob/ob and db/db mice; at the doses at which celastrol showed its strong leptin sensitizer effects, it-unlike withaferin A-was unable to reduce the blood glucose levels in the ob/ob and db/db mouse models.
Organisms respond to fasting or calorie restriction by decreasing their basal energy expenditure to compensate for decreased food intake and to preserve energy. However, it is thought that leptininduced anorexia or reduced calorie consumption does not lead to lower energy expenditure. Indeed, as for celastrol, withaferin-A treatment did not lead to reduction of energy expenditure in mice with DIO. Collectively, results obtained from treatments with withaferin A or with celastrol indicate that establishing leptin sensitivity in the context of a previous leptin-resistant condition might not increase energy expenditure to a level that is higher than in the leptin-resistant state. However, increasing leptin sensitivity through the administration of withaferin A or celastrol blocks the reduction of energy expenditure that is otherwise seen in calorie-restricted mice 41 .
Further evidence for the effects of withaferin A as a leptin sensitizer derives from experiments in which we analyzed the physiological and biochemical responses of mice to acute leptin treatment in the presence or absence of withaferin-A treatment. IHF analysis further documented that acute leptin administration in withaferin-A-treated mice, relative to the vehicle-treated group, leads to a robustly greater presence of STAT3(Tyr705) phosphorylation in the hypothalamus, particularly in the DMH and VMH, as is observed similarly with celastrol treatment.
We identified withaferin A on the basis of the similarity of its gene expression signature to that of celastrol. Whether the mechanisms for the creation of the gene expression profiles of celastrol and withaferin A are the same is not known. However, given that the leptin-independent effects of withaferin A on glucose homeostasis in ob/ob and db/db mice are not observed with the use of celastrol, it npg a r t i c l e s nature medicine VOLUME 22 | NUMBER 9 | SEPTEMBER 2016 1 0 3 1 is possible that the two compounds use different pathways to create the same outcome in their gene expression profiles, or that they use a common pathway, but that withaferin A also independently activates another antidiabetic pathway. We show that withaferin-A treatment leads to a reduction in ER stress without affecting the expression levels of most of the chaperones, and ER stress is known to create leptin resistance 28 . A recent report indicated that celastrol's anti-obesity effect could be the result of peripheral actions of celastrol, in which it promotes energy expenditure in brown and white adipose tissues through the HSF1-mediated PGC1-α activation 53 . Although celastrol could be activating the HSF1-PGC1-α axis as well, we think that this is not the main effect by which celastrol suppresses appetite and reduces body weight because we see a mild effect in ob/ob or db/db mice at the doses that we used for celastrol. Withaferin A, which has a similar gene expression profile to that of celastrol, also exerts its effects mainly on mice with DIO and not on ob/ob and db/db mice. In this sense, it is highly unlikely that the anti-obesity effect of withaferin A would be mediated through the activation of pathways that include the HSF1-PGC1-α axis in the periphery.
We identified withaferin A, another potent anti-obesity agent, without targeting a specific molecule, but rather by using the similarity in the gene expression signature of celastrol and withaferin A. We think that this methodology is a more powerful tool than screening for molecules for single targets. Indeed, more than 15 years of efforts spent on identifying single molecular targets that cause leptin resistance have not produced effective treatments for obesity. Our results indicate that improving the ER system, reducing ER stress and using the outcomes of gene expression profiling will be important future strategies for the further discovery of anti-obesity drugs.
Finally, W. somnifera extracts, which also contain withaferin A, have been used in humans for centuries 37, 38 , and the leptin system is strongly preserved among mammals, including mice and humans 54 . When all this information is considered, we think that translating the use of withaferin A for the treatment of obesity in humans holds great promise for the future.
METhODS
Methods and any associated references are available in the online version of the paper. Accession codes. Genome Expression Omnibus: microarray data have been deposited under accession codes GSE84154 and GSE84156. 
ONLINE METhODS
Reagents. Phospho-PERK(Thr980) (Clone C33E10, cat. 3192, 1:1,000 dilution for western blotting), PERK (Clone 16F8, cat. 3179, 1:1,000 dilution for western blotting), phospho-STAT3(Tyr705) (Cat. 9131; Clone D3A7, Cat. 9145; 1:1,000 dilution for western blotting; 1:3,000 dilution for immunohistofluorescence staining), STAT3 (Clone 79D7, cat. 4904, 1:1,000 dilution for western blotting), anti-tubulin (Clone 11H10, cat. 2125, 1:1,000 dilution for western blotting) and Hsp70 (Cat. 4872, 1:1,000 dilution for western blotting)-specific antibodies were purchased from Cell Signaling Technology (Beverley, MA). β-actin (Clone C4, cat. sc-47778, 1:1,000 dilution for western blotting) and Hsp90 (Clone F-8, cat. sc-13119, 1:1,000 dilution for western blotting)-specific antibodies, and horseradish peroxidase (HRP)-conjugated antirabbit and anti-mouse antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA). BM chemiluminescence western blotting substrate (POD) kit was from Roche Diagnostics (Indianapolis, IN). TRIzol reagent was from Invitrogen (Carlsbad, CA). iScript cDNA synthesis kit was purchased from Bio-Rad (Hercules, CA). RNeasy MinElute Cleanup Kit was from Qiagen (Valencia, CA). Mouse recombinant leptin was from R&D Technologies (North Kingstown, RI), and recombinant human insulin was from Eli Lilly and Company (Indianapolis, IN). Mouse leptin ELISA kit and ultra-sensitive mouse insulin enzyme-linked immunosorbent assay (ELISA) kits were from Crystal Chem (Downers Grove, IL). ALT color endpoint assay kit and AST color endpoint assay kit were from Bio Scientific (Austin, TX). Wako Cholesterol E assay kit was from Wako Diagnostics (Richmond, VA). Taqman primers, probes, Taqman universal PCR master mix, SYBR Green Super Mix, FBS and Dulbecco's Modified Eagle Medium (DMEM, with 25 mM glucose) were purchased from Life Technologies. 10% buffered formaline phosphate, and dimethyl sulfoxide (DMSO) was from Fischer BioReagents (Fremont, CA). Superfrost Plus microscopy slides and microcover glasses were purchased from VWR (Radnor, PA). TSC +/+ and TSC −/− MEFs are kindly provided by D. Kwiatkowski (Dana-Farber Cancer Institute) 55 and not tested for mycoplasma contamination. Withaferin A was purchased from ChromaDex (Irvine, CA) and celastrol was from BOC Sciences (Shirley, NY).
Animals.
The Animal Care and Use Committee at Boston Children's Hospital has approved all animal experiments conducted in this study. Males of C57BL/6J, ob/ob or db/db mice were obtained from Jackson Laboratories. C57BL/6J male mice were placed on high-fat diet (HFD, 45 kcal% from fat) at the age of 3 or 7 weeks and maintained on the same diet for 16-20 weeks. HFD was purchased from Research Diets (New Brunswick, NJ). 8-or 9-week-old ob/ob, db/db and lean mice were kept on normal chow diet (NCD, 13.5% calories from fat) that was purchased from Lab Diet (St Louis, MO). Mice were housed in a 12-h darklight cycle, with the dark cycle encompassing 7 p.m. to 7 a.m., and they had free access to food and water.
Microarray from mouse embryonic fibroblasts. We plated mouse embryonic fibroblasts (MEFs) on six 10-cm culture dishes in DMEM containing 10% FBS (FBS), and incubated them at 37 °C with 5% CO 2 . After 16 h, we removed the cell medium and washed the cells twice with DMEM containing 1% FBS. We then added 10 ml of 1% FBS DMEM with DMSO or celastrol (250 nM). After 7 h of incubation, we removed the medium from the plates, and snap-froze the culture dishes in liquid nitrogen. For RNA extraction, the plates were placed on ice for 15 s. We then added 1 ml of TRIzol reagent to the plates and incubated them at room temperature for 15 min. The cells in TRIzol were collected in 1.5-ml tubes. We then added 200 µl of chloroform and followed this by vortexing for 20 s. The tubes were centrifuged at 4 °C for 15 min at 13,400g. We transferred the clear top phase to new vials containing 400 µl of isopropanol. After 10 min of incubation at room temperature, the tubes were centrifuged at 4 °C for 12 min at 13,400g. RNA pellets were washed with 75% ethanol twice. RNA pellets were air dried for 10 min at room temperature and dissolved in 30 µl of RNase free water. We further purified the RNAs using RNeasy MinElute Cleanup Kit according to the manufacturer's protocols. 1 µg of total RNA was used for microarray analysis using Affymetrix Mouse Gene 1.0 ST arrays.
Microarray from mouse hypothalamus. We treated 12 mice with DIO that were fed on HFD for 20 weeks with vehicle for 4 consecutive days. After this acclimation period, we treated each group of four mice with DIO with vehicle, celastrol (100 µg/kg) or withaferin A (2 mg/kg) 30 min before dark cycle by intraperitoneal injection for 4 d. 14 h after the last injection, we extracted hypothalami and froze them in liquid nitrogen. We kept the hypothalamus at −80 °C until later RNA extraction. On the day of RNA extraction, we added 1 ml of TRIzol to each hypothalamus sample. The tissues were homogenized in TissueLyser II (Qiagen, Valencia, CA). We performed the hypothalamic RNA purification and microarray analysis as described in the 'Microarray from mouse embryonic fibroblasts' section.
Identifying celastrol-like leptin sensitizer using connectivity map (CMAP). As explained previously 34, 35 , CMAP is a database with a collection of gene expression data sets from cultured human cell lines treated with various small molecules. Users can search the CMAP database with two lists of genes (referred to as 'signatures' and obtained from any experimental conditions): one in which genes are upregulated and the other in which genes are downregulated. CMAP reports enrichment scores (which lie between −1 and 1) of all the drugs on the basis of relative correlations between query signature and reference gene expression profiles of individual drugs in the CMAP database. Higher positive scores for a given signature indicate that the experimental results of the particular drug treatment in CMAP show a gene expression profile similar to the signature that is provided by the user.
Administration of withaferin A. We carried out intraperitoneal injections 90 min before the dark cycle. Mice were acclimated for 4 d by daily intraperitoneal injection of vehicle (DMSO) before the start of withaferin-A injection. Withaferin A was dissolved in DMSO (25 µl) and administered to the mice intraperitoneally once a day. We injected corresponding vehicle groups intraperitoneally with a total volume of 25 µl DMSO once a day. Daily food intake (Figs. 2c,h and 3c,h ) is an average of 3-d food intake during the first week of treatment. Any deviation of the procedure is stated in the corresponding section of online methods or in figure legends.
Immunohistofluorescence staining of phospho-STAT3(Tyr705) in the hypothalamus. For celastrol treatment ( Supplementary Fig. 4 ), mice with DIO were acclimated with 25 µl of DMSO by intraperitoneal injection 60 min before the dark cycle for 4 d. Then, mice were divided into two groups, and one group was intraperitoneally injected with 25 µl of vehicle and the other with celastrol (100 µg/kg) for 3 d. 14 h after the third injection, each group of mice was injected one more time with either vehicle or celastrol (200 µg/kg). 6 h later, each group was divided into two subgroups, and each subgroup was intraperitoneally administered with either 100 µl of saline or leptin (1 mg/kg in 100 µl of saline). After 40 min of leptin or saline administration, the brain was fixated with 4% paraformaldehyde (PFA) through cardiac perfusion. After overnight fixation in 4% PFA, the brains were incubated sequentially with 20% sucrose and 30% sucrose for 2 d and frozen in Tissue-Tek OCT compound (Sakura Finetek; Torrance, CA) in dry ice. A total of 48 sections (30 µm/section, from bregma −0.9 to −2.3), including the whole arcuate nucleus (ARC), ventromedial hypothalamus (VMH) and dorsomedial hypothalamus (DMH) from each mouse, were collected using cryostat (Leica). Half of the sections (24) of each brain were subjected to pSTAT3(Tyr705) staining. The floating sections were washed with phosphate buffered saline (PBS, 3.2 mM Na 2 HPO 4 , 0.5 mM KH 2 PO 4 , 1.3 mM KCl, 135 mM NaCl, pH 7.4) for 5 min three times at room temperature and then sequentially incubated with 0.3% H 2 O 2 -1% NaOH for 20 min, 0.3% glycine for 10 min and 0.03% sodium dodecyl sulfate for 10 min. After 1 h incubation with blocking buffer (3% normal goat serum, 0.3% Triton X-100, 0.02% NaN 3 in PBS), the sections were incubated with pSTAT3(Tyr705) antibody (1:3,000 in blocking buffer; Clone D3A7, cat. 9145, Cell Signaling) for 2 d at 4 °C. After washing for 5 min with PBST (0.05% Tween 20 in PBS) three times, the sections were incubated with fluorescein isothiocyanate (FITC)-conjugated goat anti-rabbit IgG for 1 h at room temperature. After three additional washes with PBST, the sections were placed in microscopy glasses, covered with cover glasses and then subjected to image analysis. The image from the whole hypothalamic area of each section was acquired with a ZEISS 710 confocal microscope under 20× objective (tile scan, resolution: 512 × 512 pixels). The sections without detectable pSTAT3(Tyr705) signal were not subjected to npg image processing. Therefore, a total of 154 images for Veh + Sal, 166 images for Veh + Lep, 167 images for Wit A + Sal and 167 images for Wit A + Lep group were analyzed for Figure 4b-g. A total of 93 images for Veh + Sal, 95 images for Veh + Lep, 98 images for Cel + Sal and 97 images for the Cel + Lep group were used for the analysis in Supplementary Figure 4 . The pSTAT3(Tyr705)-positive cell numbers and fluorescence intensities representing pSTAT3(Tyr705) were blindly analyzed by using ImageJ software with the option of analysis particle, which determined the area of measurement and calculated the mean gray value, particle numbers and integrated fluorescence densities. The same setting was applied for all image analyses. The sum of cell numbers (pSTAT3(Tyr705)-positive total cell number, TCN) and fluorescence intensities (pSTAT3(Tyr705) positive total fluorescence intensity) from sections of ARC, VMH and DMH of each brain were calculated and presented as the percentage to control group (vehicle plus saline treated group).
For withaferin-A treatment (Fig. 4b-g ), mice with DIO were acclimated with vehicle 60 min before the dark cycle for 4 d. Then, mice were divided into two groups that received either vehicle or withaferin A (2 mg/kg) for 3 d. 14 h after the final injection, each group of mice was further divided into two subgroups, and one subgroup was intraperitoneally injected with 100 µl of saline, and the other subgroup was given leptin (1 mg/kg in 100 µl of saline). After 40 min of leptin or saline injection, the brain was fixated and samples were analyzed as described above.
Leptin administration, and food intake and body-weight measurements. We administered vehicle or withaferin A (1.5 mg/kg) intraperitoneally once a day for 2 d, 90 min before dark cycle, to mice with DIO. 1 h after the second injection, we further divided the vehicle and withaferin A-injected groups into two subgroups. Each subgroup of mice received either saline or leptin (1 mg/kg, intraperitoneally). Food intake and body-weight changes were measured 15 h after saline or leptin administrations (Supplementary Fig. 3a,b) . Supplementary  Figure 3c ,d, we treated 8-week-old male ob/ob mice with either vehicle or withaferin A (1 mg/kg) for 5 consecutive days after 4-d acclimation with vehicle. On the sixth day after this process, we divided each group of mice into two subgroups and injected each subgroup with either saline or leptin (0.1 mg/kg), together with vehicle or withaferin A, for 2 more weeks. Therefore, we had four groups: vehicle plus saline, vehicle plus leptin, withaferin A plus saline and withaferin A plus leptin treatment. We recorded food intake and body weights of each mouse daily. The percentage of suppression in food intake for vehicle and withaferin-A groups during the second week of leptin treatment is calculated as follows: 100 × (food intake of leptin group)/(food intake of saline group).
Leptin administration to ob/ob mice. For experiments in
Metabolic cage measurements.
For metabolic chamber measurements, we used three different mouse models: male mice with DIO that were fed on HFD for 16 weeks and 8-week-old male ob/ob and db/db on regular chow diet. We caged mice individually for at least 1 week before performing the metabolic chamber experiments. We used Columbus Instruments Comprehensive Lab Animal Monitoring System (CLAMS) for metabolic measurements. Mice were pre-treated with vehicle (DMSO) by intraperitoneal injection for 4 d (acclimation period) and placed into the metabolic chambers on the fifth day. We then injected them with either vehicle or withaferin A (1.5 mg/kg) for 3 consecutive days in the metabolic cages. Mice had free access to food and water. Energy expenditure (EE) and RER were measured by indirect calorimetry. We measured volumetric rate of oxygen consumption (VO 2 ) and carbon dioxide production (VCO 2 ) by CLAMS, and EE and RER are calculated according to the following formulas:
